Beta Bionics, Inc. — Director's Dealing 2025

Feb 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-01-31

Reporting Person: Mensinger Mike (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-31	Common Stock	C	15107	—	Acquired	15107	Direct
2025-01-31	Common Stock	X	10575	$0.02	Acquired	25682	Direct
2025-01-31	Common Stock	S	13	$17	Disposed	25669	Direct
2025-01-31	Common Stock	P	33350	$17	Acquired	59019	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-31	Series D Preferred Stock	$	C	15107	Disposed		Common Stock (15107)	Direct
2025-01-31	Class B Common Stock Warrant (right to buy)	$0.02	C	10575	Acquired	2033-08-27	Common Stock (10575)	Direct
2025-01-31	Class B Common Stock Warrant (right to buy)	$0.02	X	10575	Disposed	2033-08-27	Common Stock (10575)	Direct
2025-01-31	Employee Stock Option (right to buy)	$5.10	A	236553	Acquired	2033-09-13	Common Stock (236553)	Direct
2025-01-31	Employee Stock Option (right to buy)	$17	A	110278	Acquired	2025-01-28	Common Stock (110278)	Direct

Footnotes

F1: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.

F2: On January 31, 2025, the reporting person exercised a warrant to purchase 10,575 shares of Issuer's common stock for $0.02 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in withholding of 13 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 10,562 shares.

F3: The shares were purchased in the Issuer's initial public offering.

F4: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this warrant was converted into an equal number of shares of Common Stock.

F5: One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.

F6: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.

F7: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.